Annual Interest Expense
$29.58 M
-$3.04 M-9.33%
December 31, 2023
Summary
- As of February 7, 2025, APLS annual interest expense is $29.58 million, with the most recent change of -$3.04 million (-9.33%) on December 31, 2023.
- During the last 3 years, APLS annual interest expense has fallen by -$356.00 thousand (-1.19%).
- APLS annual interest expense is now -9.33% below its all-time high of $32.63 million, reached on December 31, 2022.
Performance
APLS Interest Expense Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Interest Expense
$12.53 M
+$3.17 M+33.90%
September 30, 2024
Summary
- As of February 7, 2025, APLS quarterly interest expense is $12.53 million, with the most recent change of +$3.17 million (+33.90%) on September 30, 2024.
- Over the past year, APLS quarterly interest expense has increased by +$5.13 million (+69.31%).
- APLS quarterly interest expense is now at all-time high.
Performance
APLS Quarterly Interest Expense Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM Interest Expense
$36.26 M
+$5.22 M+16.82%
September 30, 2024
Summary
- As of February 7, 2025, APLS TTM interest expense is $36.26 million, with the most recent change of +$5.22 million (+16.82%) on September 30, 2024.
- Over the past year, APLS TTM interest expense has increased by +$6.68 million (+22.57%).
- APLS TTM interest expense is now at all-time high.
Performance
APLS TTM Interest Expense Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Interest Expense Formula
Interest Expense = Carrying Value of Debt X Effective Interest Rate
APLS Interest Expense Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -9.3% | +69.3% | +22.6% |
| 3 y3 years | -1.2% | +315.2% | +173.8% |
| 5 y5 years | +1077.1% | +315.2% | +173.8% |
APLS Interest Expense Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -9.3% | +123.4% | at high | +315.2% | at high | +173.8% |
| 5 y | 5-year | -9.3% | +459.7% | at high | +449.2% | at high | +586.1% |
| alltime | all time | -9.3% | -100.0% | at high | +7781.8% | at high | +5335.5% |
Apellis Pharmaceuticals Interest Expense History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $12.53 M(+33.9%) | $36.26 M(+16.8%) |
| Jun 2024 | - | $9.36 M(+34.3%) | $31.04 M(+7.0%) |
| Mar 2024 | - | $6.97 M(-5.9%) | $29.02 M(-1.9%) |
| Dec 2023 | $29.58 M(-9.3%) | $7.40 M(+1.3%) | $29.58 M(-1.1%) |
| Sep 2023 | - | $7.31 M(-0.4%) | $29.92 M(-1.9%) |
| Jun 2023 | - | $7.34 M(-2.5%) | $30.51 M(-3.5%) |
| Mar 2023 | - | $7.53 M(-2.7%) | $31.62 M(-3.1%) |
| Dec 2022 | $32.63 M(+146.4%) | $7.74 M(-2.1%) | $32.63 M(+16.9%) |
| Sep 2022 | - | $7.90 M(-6.5%) | $27.91 M(+25.2%) |
| Jun 2022 | - | $8.45 M(-1.1%) | $22.29 M(+26.6%) |
| Mar 2022 | - | $8.54 M(+182.9%) | $17.61 M(+32.9%) |
| Dec 2021 | $13.24 M | $3.02 M(+32.3%) | $13.24 M(-33.2%) |
| Sep 2021 | - | $2.28 M(-39.4%) | $19.83 M(-26.7%) |
| Jun 2021 | - | $3.77 M(-9.8%) | $27.05 M(-10.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | $4.17 M(-56.6%) | $30.19 M(+0.9%) |
| Dec 2020 | $29.94 M(+466.5%) | $9.61 M(+1.2%) | $29.94 M(+23.4%) |
| Sep 2020 | - | $9.50 M(+37.5%) | $24.26 M(+57.9%) |
| Jun 2020 | - | $6.91 M(+76.3%) | $15.36 M(+78.4%) |
| Mar 2020 | - | $3.92 M(-0.3%) | $8.61 M(+62.9%) |
| Dec 2019 | $5.29 M(+110.3%) | $3.93 M(+553.0%) | $5.29 M(+103.6%) |
| Sep 2019 | - | $602.00 K(+278.6%) | $2.60 M(+1.0%) |
| Jun 2019 | - | $159.00 K(-73.2%) | $2.57 M(-14.7%) |
| Mar 2019 | - | $593.00 K(-52.3%) | $3.02 M(-2.4%) |
| Dec 2018 | $2.51 M(+570.7%) | $1.24 M(+115.1%) | $3.09 M(+67.2%) |
| Sep 2018 | - | $577.50 K(-4.3%) | $1.85 M(+45.4%) |
| Jun 2018 | - | $603.70 K(-9.5%) | $1.27 M(+90.5%) |
| Mar 2018 | - | $667.10 K | $667.10 K |
| Dec 2017 | $374.70 K(>+9900.0%) | - | - |
| Dec 2016 | $0.00 | - | - |
FAQ
- What is Apellis Pharmaceuticals annual interest expense?
- What is the all time high annual interest expense for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals annual interest expense year-on-year change?
- What is Apellis Pharmaceuticals quarterly interest expense?
- What is the all time high quarterly interest expense for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals quarterly interest expense year-on-year change?
- What is Apellis Pharmaceuticals TTM interest expense?
- What is the all time high TTM interest expense for Apellis Pharmaceuticals?
- What is Apellis Pharmaceuticals TTM interest expense year-on-year change?
What is Apellis Pharmaceuticals annual interest expense?
The current annual interest expense of APLS is $29.58 M
What is the all time high annual interest expense for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high annual interest expense is $32.63 M
What is Apellis Pharmaceuticals annual interest expense year-on-year change?
Over the past year, APLS annual interest expense has changed by -$3.04 M (-9.33%)
What is Apellis Pharmaceuticals quarterly interest expense?
The current quarterly interest expense of APLS is $12.53 M
What is the all time high quarterly interest expense for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high quarterly interest expense is $12.53 M
What is Apellis Pharmaceuticals quarterly interest expense year-on-year change?
Over the past year, APLS quarterly interest expense has changed by +$5.13 M (+69.31%)
What is Apellis Pharmaceuticals TTM interest expense?
The current TTM interest expense of APLS is $36.26 M
What is the all time high TTM interest expense for Apellis Pharmaceuticals?
Apellis Pharmaceuticals all-time high TTM interest expense is $36.26 M
What is Apellis Pharmaceuticals TTM interest expense year-on-year change?
Over the past year, APLS TTM interest expense has changed by +$6.68 M (+22.57%)